Baseline Serum Metabolites as Predictors of Teplizumab Response in Individuals With Type 1 Diabetes.

Authors

Elizabeth R Flammer, Lauren E Higdon, Srinath Sanda, Todd M Brusko, Timothy J Garrett, Heba M Ismail

Published in

Diabetes. Aug 18, 2026. Epub Aug 18, 2026.

Abstract

We believed that baseline serum metabolomic signatures can predict response to immunotherapies to identify which individuals will benefit most from treatment. We aimed to identify whether baseline serum metabolomic profiles can distinguish responders from nonresponders to teplizumab. Fifteen metabolites were identified as significantly different. Our findings suggest that baseline serum metabolomic signatures could be used to predict which newly diagnosed type 1 diabetes patients will respond to teplizumab, enabling more personalized treatment decisions.

PMID:
42610933
Bibliographic data and abstract were imported from PubMed on 18 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.